Target MAP for LVAD Patients
The goal MAP for patients with continuous-flow LVADs is less than 80 mm Hg, measured using Doppler opening pressure method. 1
Specific Target Ranges by Device Type
HVAD Devices
- Target MAP: 60-80 mm Hg using Doppler opening pressure 1
- Alternative targets based on pulse presence:
HeartMate 3 Devices
- Target MAP: 80-90 mm Hg 2
- This represents a slightly higher range compared to HVAD, though the evidence for optimal targets is less well-defined for this device
General Continuous-Flow LVADs
- ISHLT guideline recommendation: MAP <80 mm Hg 1
- Older Canadian guidelines suggest MAP ≤90 mm Hg, preferably ≤85 mm Hg 3
Critical Thresholds to Avoid
Lower Limit (Hypotension Risk)
Avoid MAP ≤75 mm Hg - this threshold is associated with significantly increased mortality and adverse outcomes:
- 35-42% higher adjusted hazard of death compared to normal BP 4
- 4.74-fold increased risk of death (HR 4.74,95% CI 2.85-7.87) 5
- 2.72-fold increased risk of stroke (HR 2.72,95% CI 1.39-5.33) 5
- Associated with low cardiac output, residual heart failure symptoms, and ventricular arrhythmias 1
Upper Limit (Hypertension Risk)
Avoid MAP >100 mm Hg - excessive blood pressure increases complications:
- 17-20% higher adjusted hazard of death compared to normal pressures 4
- Uncontrolled hypertension causes low cardiac output, residual HF symptoms, and ventricular arrhythmias 1
- Increased risk of hemorrhagic stroke, particularly with HVAD devices 1, 2
- May promote aortic insufficiency development 6
Measurement Technique
Use Doppler opening pressure method - this is the preferred and validated approach:
- Wide availability, reliability, and validated accuracy across all FDA-approved continuous-flow VAD systems 1
- Traditional oscillometric cuffs and auscultation are unreliable due to diminished pulse pressure 1
- Doppler correlates strongly with invasive MAP (r = 0.78-0.91, bias -0.35 mmHg) 7
- In patients with symptoms (dizziness, headache, abnormal VAD flow) despite Doppler at goal, consider arterial line study to establish individualized target 1
Clinical Rationale
The narrow MAP target range exists because continuous-flow LVADs are afterload-sensitive devices:
- Hypertension consequences: At fixed pump speed, elevated aortic pressure reduces pump flow, leading to inadequate cardiac output and end-organ dysfunction 1
- Hypotension consequences: Excessively low BP causes excess LV unloading, RV volume overload, and suction events, especially with small LV dimensions 1
- Stroke prevention: Enhanced BP protocols in the ENDURANCE Supplemental trial reduced stroke rates by 24.2% and hemorrhagic strokes by 50.5% compared to less stringent control 1, 2
Pharmacologic Management
After LVAD implantation, most patients require antihypertensive therapy:
- First-line agents: ACE inhibitors, ARBs, or angiotensin receptor-neprilysin inhibitors (85% of patients on antihypertensives) 1, 6
- Second-line: Beta-blockers (30% of patients), reserved until euvolemic with adequate RV function 1, 6
- Immediate postoperative: Hydralazine (renal-neutral) 1
- Medication burden: 54% require 1 medication, 34% require 2,10% require 3 or more 6
Common Pitfalls
- Over-aggressive BP lowering: Targeting MAP <75 mm Hg significantly increases mortality risk - this is the most dangerous error 4, 5
- Using wrong measurement method: Oscillometric cuffs fail or provide inaccurate readings in LVAD patients 1
- Assuming Doppler = systolic pressure: In patients with aortic valve opening, Doppler may approximate systolic rather than mean pressure 1
- Ignoring device-specific differences: HVAD has flatter pump head-flow curve than HeartMate devices, making it more sensitive to BP changes 1
The evidence consistently supports maintaining MAP between 75-80 mm Hg as the optimal range, with strict avoidance of values below 75 mm Hg due to substantially increased mortality risk.